Characterization of gangliosides in human uveal melanoma cells

We have evaluated the ganglioside composition of 20 primary uveal melanomas, of 2 cell lines derived from 2 uveal melanomas, of a liver metastasis from an uveal melanoma, and 8 of normal choroids. The results show that normal choroid tissue has a ganglioside content similar to the primary tumors of uveal melanoma except for GD1a, GD1b, and GT1b, which are present only on normal choroid tissues. On the other hand, the uveal melanomas have similarities with cutaneous melanomas, since GM3 (74%) and GD3 (25%) are found in both tissues and are present in about the same amounts. However, GM1 was found in 50%, GM2 in 20% and GD2 in none of the uveal melanomas. According to data published by others, cutaneous melanoma biopsies have no GM1, whereas GM2 is present in 100% and GD2 in 71% of tumor tissues. Transplantation of the 2 cell lines subcutaneously into nude mice resulted in the growth of tumors which had a ganglioside profile larger than that of the primary tumors. GM3 was significantly diminished and GD3 significantly increased in the primary uveal melanoma from patients who had received radiotherapy before enucleation compared with those who did not have radiotherapy. These results show that uveal melanomas contain gangliosides that could be used as targets for monoclonal antibody therapy.

[1]  D. Robertson.  A rationale for comparing radiation to enucleation in the management of choroidal melanoma. , 1989, American journal of ophthalmology.

[2]  D. Morton,et al.  An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. , 1989, Cancer research.

[3]  R. Saxton,et al.  Gangliosides of human melanoma , 1989, Cancer.

[4]  K. Furukawa,et al.  The addition of exogenous gangliosides to cultured human cells results in the cell type-specific expression of novel surface antigens by a biosynthetic process. , 1989, Journal of immunology.

[5]  C. Cordon-Cardo,et al.  Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Werkmeister,et al.  Synergism between membrane gangliosides and Arg-Gly-Asp-directed glycoprotein receptors in attachment to matrix proteins by melanoma cells , 1988, The Journal of cell biology.

[7]  H. Higashi,et al.  Detection of Gangliosides as N‐Glycolylneuraminic Acid‐specific Tumor‐associated Hanganutziu‐Deicher Antigen in Human Retinoblastoma Cells , 1988, Japanese journal of cancer research : Gann.

[8]  S. Hakomori,et al.  A novel ganglioside, de-N-acetyl-GM3 (II3NeuNH2LacCer), acting as a strong promoter for epidermal growth factor receptor kinase and as a stimulator for cell growth. , 1988, The Journal of biological chemistry.

[9]  M. Taniguchi,et al.  Escape mechanisms of melanoma from immune system by soluble melanoma antigen. , 1988, Journal of immunology.

[10]  A. Cochran,et al.  Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2. , 1988, Cellular immunology.

[11]  C. Cordon-Cardo,et al.  Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. , 1987, Journal of immunology.

[12]  N. Berger,et al.  Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Saxton,et al.  Gangliosides of human melanoma: altered expression in vivo and in vitro. , 1987, Cancer research.

[14]  D. Morton,et al.  Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Melamed,et al.  Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. , 1985, Cancer research.

[16]  J. Gass.  Comparison of prognosis after enucleation vs cobalt 60 irradiation of melanomas. , 1985, Archives of ophthalmology.

[17]  S. Ladisch,et al.  A solvent partition method for microscale ganglioside purification. , 1985, Analytical biochemistry.

[18]  M. Melamed,et al.  Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[19]  M. Melamed,et al.  Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody , 1984, Brain Research.

[20]  D. Albert,et al.  Establishment of cell lines of uveal melanoma. Methodology and characteristics. , 1984, Investigative ophthalmology & visual science.

[21]  D. Cheresh,et al.  Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Kirkwood,et al.  Gangliosides of normal and neoplastic human melanocytes. , 1984, Biochemical and biophysical research communications.

[23]  S. Hakomori,et al.  Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2. , 1982, The Journal of biological chemistry.

[24]  L. Zimmerman,et al.  An Evaluation of Enucleation in the Management of Uveal Melanomas , 1979, American journal of ophthalmology.

[25]  A. E. Maumenee,et al.  An evaluation of enucleation in the management of uveal melanomas. , 1979, American journal of ophthalmology.

[26]  S. Shapiro,et al.  An Analysis of Variance Test for Normality (Complete Samples) , 1965 .

[27]  L. Svennerholm.  CHROMATOGRAPHlC SEPARATION OF HUMAN BRAIN GANGLIOSIDES * , 1963, Journal of neurochemistry.

[28]  C. Dumontet,et al.  [Gangliosides and cancer]. , 1991, Bulletin du cancer.

[29]  M. Grossin,et al.  [Immunohistochemical markers of malignant melanoma]. , 1990, Annales de pathologie.

[30]  K. Kono,et al.  Ganglioside composition of human melanoma and response to antitumor treatment. , 1990, Cancer investigation.

[31]  D. Cheresh,et al.  Enzymatic basis for increased expression of GD3 on human melanoma cells derived from metastatic lesions , 1988 .

[32]  R. Yu,et al.  Gangliosides: structure, isolation, and analysis. , 1982, Methods in enzymology.

[33]  L. Svennerholm.  Quantitative estimation of sialic acids. II. A colorimetric resorcinol-hydrochloric acid method. , 1957, Biochimica et biophysica acta.